Amgen "market perform," target price reduced

03.03.07 - Friedman,Billings,Ramsey &Co

NEW YORK, March 3 (newratings.com) - In a research note published yesterday, analysts at Friedman Billings reiterate their "market perform" rating on Amgen (AMGN). The target price has been reduced from $73 to $65.